Introduction Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces a
dysregulated hyperinflammatory response. Areas covered Authors review evidence on IL-6 …

The identification of elevated IL-6 levels in patients with severe COVID-19 led to the rapid
development of clinical trials targeting this cytokine. Overall, these trials do not support the …

Abstract Interleukin-6 (IL-6) is a pleiotropic cytokine with effects in immune regulation,
inflammation, and infection. The use of drugs that inhibit IL-6 biological activity has been …

Coronaviruses may activate dysregulated host immune responses. As exploratory studies
have suggested that interleukin‐6 (IL‐6) levels are elevated in cases of complicated Covid …

Summary Objectives Multiple RCTs of interleukin-6 (IL-6) inhibitors in COVID-19 have been
published, with conflicting conclusions. We performed a meta-analysis to assess the impact …

Background: Interleukin-6 (IL-6) is known to be detrimental in coronavirus disease 2019
(COVID-19) because of its involvement in driving cytokine storm. This systematic review and …

Cytokine storm syndrome (CSS) is a severe complication of inflammatory immune diseases
or treatment of malignancies; it may also appear during the progression of COVID-19. CSS …

Acting on the cytokine cascade is key to preventing disease progression and death in
hospitalised patients with COVID-19. Among anti-cytokine therapies, interleukin (IL)-6 …

The epidemic due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
infection has been spreading globally, raising increasing concerns. This public health …

COVID-19 mortality is strongly associated with the development of severe pneumonia and
acute respiratory distress syndrome with the worst outcome resulting in cytokine release …